Added to YB: 2026-07-20
Pitch date: 2026-07-16
INM [neutral]
InMed Pharmaceuticals Inc.
Author Info
No bio for this author
Company Info
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.
Market Cap
$7.1M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.30
P/E
-0.68
EV/Sales
0.47
Sector
Pharmaceuticals
Category
special_situation
INM | InMed Pharmaceuticals: The Next Paragon Spinoff Gets One Step Closer
INM (overview): Reverse merger with private migraine biotech Mentari Therapeutics; combined co valued ~$421M backed by oversubscribed $290M PIPE (funds ops thru 2028). InMed a $5-8M shell (~$1.55-1.60/sh) wrapping Mentari's anti-PACAP/CGRP pipeline. S-4 filed 7/2/26, close Q4 2026; rename to Mentari, redomicile to Nevada, reverse split likely. Flagged as Paragon-style pattern to watch, not adding today. Clinical readouts 2027-28.
Read full article (2 min)